{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:46:03Z","timestamp":1775742363565,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ijcard.2003.10.004","type":"journal-article","created":{"date-parts":[[2003,12,31]],"date-time":"2003-12-31T07:13:11Z","timestamp":1072854791000},"page":"137-141","source":"Crossref","is-referenced-by-count":12,"title":["From CONSENSUS to CHARM\u2014how do ACEI and ARB produce clinical benefits in CHF?"],"prefix":"10.1016","volume":"94","author":[{"given":"L.B.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.F.","family":"Goldspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2003.10.004_BIB1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function talking angiotension converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB5","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/hc0302.102618","article-title":"The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis","volume":"105","author":"Nickenig","year":"2002","journal-title":"Circulation"},{"issue":"Suppl. 6","key":"10.1016\/j.ijcard.2003.10.004_BIB9","doi-asserted-by":"crossref","first-page":"S556","DOI":"10.1054\/jcaf.2002.129271","article-title":"Future strategies of reverse remodelling: summation","volume":"8","author":"Poole-Wilson","year":"2002","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","article-title":"Remodeling of the rat right and left ventricle in experimental hypertension","volume":"67","author":"Brilla","year":"1990","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/01.CIR.102.12.1388","article-title":"Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease","volume":"102","author":"Brilla","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/174182679400100311","article-title":"Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II","volume":"1","author":"Stauss","year":"1994","journal-title":"J. Cardiovasc. Risk"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.HYP.23.4.411","article-title":"Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin","volume":"23","author":"Gohlke","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0008-6363(98)00090-X","article-title":"Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin","volume":"39","author":"Hu","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3317\/jraas.2000.017","article-title":"The renin angiotensin system and cardiovascular disease: hope or hype?","volume":"1","author":"Williams","year":"2000","journal-title":"J. Renin Angiotension Aldosterone System"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB16","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1161\/hy1101.099502","article-title":"Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy","volume":"38","author":"Svensson","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB17","first-page":"13","article-title":"Modifying the natural history of atherosclerosis: the SECURE trial","volume":"117","author":"Lonn","year":"2001","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11883-002-0074-7","article-title":"ACE inhibitors and angiotensin receptor blockers in atherosclerosis","volume":"4","author":"Lonn","year":"2002","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0002-9343(01)01001-4","article-title":"Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease","volume":"112","author":"Halkin","year":"2002","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/hrt.58.3.190","article-title":"Congestive cardiac failure: central role of the arterial blood pressure","volume":"58","author":"Harris","year":"1987","journal-title":"Br. Heart J."},{"issue":"8593","key":"10.1016\/j.ijcard.2003.10.004_BIB21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(88)91852-1","article-title":"Role of arterial pressure in the oedema of heart disease","volume":"i","author":"Harris","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB22","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.94.4.690","article-title":"Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators","volume":"94","author":"Benedict","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1388-9842(01)00181-7","article-title":"Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations","volume":"3","author":"Groenning","year":"2001","journal-title":"Eur. J. Heart Fail."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2003.10.004_BIB25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199000392-00004","article-title":"Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE","volume":"39","author":"Dzau","year":"1990","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2003.10.004_BIB26","first-page":"1","article-title":"Local expression and pathophysiological role of renin\u2013angiotensin in the blood vessels and heart","volume":"88","author":"Dzau","year":"1993","journal-title":"Basic Res. Cardiol."},{"issue":"Suppl. 9","key":"10.1016\/j.ijcard.2003.10.004_BIB27","doi-asserted-by":"crossref","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.RES.65.3.657","article-title":"Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis","volume":"65","author":"Benjamin","year":"1989","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cvr\/26.6.608","article-title":"Beta-adrenergic receptor desensitization may serve a cardioprotective role","volume":"26","author":"Tan","year":"1992","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.RES.69.5.1185","article-title":"Cardiac myocyte necrosis induced by angiotensin II","volume":"69","author":"Tan","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB31","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/en.141.10.3871","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB32","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1006\/jmcc.2002.2115","article-title":"Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rats","volume":"34","author":"De Angelis","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00045415-200203000-00008","article-title":"Aldosterone as a mediator in cardiovascular injury","volume":"10","author":"Stier","year":"2002","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0167-5273(02)00369-8","article-title":"Isoprenaline induces myocyte necrosis in rat skeletal muscle: comparison with effects on cardiomyocytes","volume":"86","author":"Ng","year":"2002","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00005344-200304000-00003","article-title":"Characterisation of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents","volume":"41","author":"Tan","year":"2003","journal-title":"J. Cardiovasc. Pharm."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1113\/eph8802549","article-title":"Cardiomyocyte death and the ageing and failing heart","volume":"88","author":"Goldspink","year":"2003","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2362.2002.00998.x","article-title":"Relevance of apoptosis and cell proliferation for survival of patients with dilated cardiomyopathy undergoing partial left ventriculectomy","volume":"32","author":"Metzger","year":"2002","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1046\/j.1365-2362.1999.00481.x","article-title":"Cardiomyocyte apoptosis and progression of heart failure to transplantation","volume":"29","author":"Saraste","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB39","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199610173351603","article-title":"Apoptosis in myocytes in end-stage heart failure","volume":"335","author":"Narula","year":"1996","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB40","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.RES.68.6.1560","article-title":"Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy","volume":"68","author":"Olivetti","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB41","first-page":"H626","article-title":"Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure","volume":"275","author":"Goussev","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB42","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0735-1097(00)00913-X","article-title":"Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure","volume":"36","author":"Sabbah","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00004872-200206000-00010","article-title":"Prejunctional modulation of sympathetic tone by angiotensin II receptor antagonists: are there relevant differences?","volume":"20","author":"Kiowski","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB44","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00001573-200305000-00007","article-title":"Role of cardiac power in heart failure","volume":"18","author":"Cotter","year":"2003","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB45","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1053\/euhj.2000.2547","article-title":"Peak cardiac power output: a powerful prognostic indicator in chronic heart failure","volume":"22","author":"Williams","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB46","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(98)11472-1","article-title":"Shifts in mortality curves: saving or extending lives?","volume":"354","author":"Tan","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB47","first-page":"65","article-title":"Applying mortality curves to general practice","volume":"14","author":"Tan","year":"2003","journal-title":"Prescriber"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB48","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0167-5273(00)00438-1","article-title":"Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design","volume":"77","author":"Williams","year":"2001","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/euhj.2001.3112","article-title":"A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients","volume":"23","author":"Cooke","year":"2002","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1388-9842(03)00043-6","article-title":"Ventriculo-arterial function curves\u2014a new dimension in characterising acute heart failure","volume":"5","author":"Tan","year":"2003","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/hh0701.089175","article-title":"Enhanced angiotensin II activity in heart failure: re-evaluation of the counterregulatory hypothesis of receptor subtypes","volume":"88","author":"Opie","year":"2001","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB55","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2003.10.004_BIB56","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ijcard.2003.10.004_BIB59","first-page":"310","article-title":"Aldosterone antagonists: current and future perspectives","volume":"2","author":"Williams","year":"2000","journal-title":"Curr. Opin. Cardiovasc. Pulmon. Renal Invest. Drugs"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527303004169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527303004169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T15:28:31Z","timestamp":1550244511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527303004169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":59,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0167527303004169"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2003.10.004","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}